TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic SummitAt the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform.

LAS VEGAS – October 27, 2022 – (Newswire.com)

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating their AI-enabled drug discovery engines’ ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California. In her session entitled “The Use of an AI-enabled Drug Discovery Engine to Identify Plant-Inspired Pharmaceuticals,” Dr. Small-Howard will introduce PhAROS™, Gb Sciences’ proprietary AI-enabled drug discovery platform. Dr. Small-Howard will also present case studies establishing how the company has utilized PhAROS™ to combine information from plant-based medical systems with modern in silico drug discovery tools that identify novel plant-inspired therapies for treating critical medical needs. 

“Gb Sciences is combining knowledge from plant-based traditional medical systems with modern in silico drug discovery tools. We are leveraging our AI-enabled platform with its unique database of known traditional medical plant species to uncover novel minimum essential mixtures of ingredients with therapeutic benefits and reduced side effect profiles. Our AI-enabled drug discovery platform also reduces the time and money needed to get results,” said Dr. Andrea Small-Howard. “With current drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain or novel options for patients suffering with anxiety and depression, we are establishing the value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures.”

Dr. Andrea Small-Howard of Gb Sciences was recently featured on MarketScale’s “IDC with Kevin Stevenson” podcast in an episode entitled “Bringing Medicines to Market Faster Through Analytics and Machine Learning” where she discussed the need for digital transformation in the biopharma industry and the fact that Gb Sciences is ahead of the majority of the industry through the development and use of their PhAROS™ platform for drug discovery. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 TestSenzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo’s Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

PHILADELPHIA – October 27, 2022 – (Newswire.com)

 This contract follows Senzo’s recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.

Senzo’s core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry’s gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests.

“The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it’s that simple. BARDA’s support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market,” said Jeremy Stackawitz, CEO of Senzo.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com.

Contact Information:

Alex Mohacs

Sales & Marketing

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

Author Aleta Spencer’s New Book ‘The Pumpkin Blessing’ is an Adorable Story of a Talking Pumpkin That Wishes to Do More in His Life by Spreading Christ’s Message

Author Aleta Spencer’s New Book ‘The Pumpkin Blessing’ is an Adorable Story of a Talking Pumpkin That Wishes to Do More in His Life by Spreading Christ’s MessageRecent release “The Pumpkin Blessing” from Covenant Books author Aleta Spencer is a charming tale that follows a pumpkin as he makes friends with a beautiful white dove. Dove explains to Little Pumpkin all about God and the story of Jesus Christ, which inspires the pumpkin to pray to God and ask for a way to spread His love and honor Him in his life.

INDEPENDENCE, Mo. – October 27, 2022 – (Newswire.com)

Aleta Spencer, who spent many years working with children, several of which were while teaching at a Christian school, has completed her new book, “The Pumpkin Blessing”: a poignant tale of a small pumpkin who, after learning about God and prayer, wishes to spend the rest of his days honoring the Lord and sharing His messages of love and light to all.

“The Pumpkin Blessing is the story of a young pumpkin befriended by a white dove. Dove teaches him about God. As a result, Little Pumpkin wants to help tell people about God’s love but doesn’t know how, so he asks God,” writes Spencer.

“He learns to worship, pray, and exercise faith as he waits for the answer. Along the way, he finds comfort and encouragement from other worshippers and experiences God’s protection.

“As he matures, he grows from wanting everything his way to complete acceptance and surrender to God—and gets his heart’s desire.”

Published by Covenant Books of Murrells Inlet, South Carolina, Aleta Spencer’s new book is an enlightening tale that shows how, much like Little Pumpkin, readers of all backgrounds can shine God’s light on anyone and spread God’s love and glory to all those willing to accept it.

Readers can purchase “The Pumpkin Blessing” at bookstores everywhere, or online at the Apple iTunes store, Amazon or Barnes & Noble.

Covenant books is an international Christian owned and operated publishing house based in Murrells Inlet, South Carolina. Covenant Books specializes in all genres of work which appeal to the Christian market. For additional information or media inquiries, contact Covenant Books at 843-507-8373.   

Contact Information:

Covenant Books Media Department

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Author Aleta Spencer’s New Book ‘The Pumpkin Blessing’ is an Adorable Story of a Talking Pumpkin That Wishes to Do More in His Life by Spreading Christ’s Message

Diane Fendrock-McFarlane’s New Book ‘Back in My Day’ is a charming tale of the ways in which times and expectations have changed since the author’s childhood

Diane Fendrock-McFarlane’s New Book ‘Back in My Day’ is a charming tale of the ways in which times and expectations have changed since the author’s childhood

WILKES-BARRE, Pa. – October 27, 2022 – (Newswire.com)

Fulton Books author Diane Fendrock-McFarlane, a school counselor for the Wilkes-Barre Area School District who graduated from Wilkes University and the University of Scranton, has completed her most recent book “Back in My Day”: an engaging tale that takes a look back at the ways in which times have changed, and imagines what things might be like in the future.

“‘Back in My Day’ is a realization that, as an adult, you are turning into your parents!” shares Fendrock-McFarlane. “When you finally realize that you are referring back to the days when life seemed a little more challenging and share your younger experiences with children, there is no turning back. Children tend to laugh at the extremes that adults went through in their younger days…and how we could have barely made it to adulthood. Share these whimsical stories with the younger generation and challenge them to think of what they will tell children when they finally refer to their younger days and remember…’Back in my day.'”

Published by Fulton Books, Diane Fendrock-McFarlane’s book is an incredible look back in time when technology and times were much simpler and will fill older readers with nostalgia for a bygone era, while inspiring younger readers to appreciate the ways in which their lives have been made easier.

Readers who wish to experience this adorable work can purchase “Back in My Day” at bookstores everywhere, or online at the Apple iTunes Store, Amazon, Google Play, or Barnes & Noble.

Please direct all media inquiries to Author Support via email at [email protected] or via telephone at 877-210-0816.

Contact Information:

Media Relations

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Diane Fendrock-McFarlane’s New Book ‘Back in My Day’ is a charming tale of the ways in which times and expectations have changed since the author’s childhood

Author Terol McCullar (T-Mac)’s New Book ‘Hoggs II: Prison Journals’ Offers Unique Insight Into the Eventful and Challenging Lives of Prison Staff

Author Terol McCullar (T-Mac)’s New Book ‘Hoggs II: Prison Journals’ Offers Unique Insight Into the Eventful and Challenging Lives of Prison StaffRecent release “Hoggs II: Prison Journals” from Newman Springs Publishing author Terol McCullar (T-Mac) delivers more true accounts of the staff’s daily lives and interactions with inmates in the State of California Department of Corrections.

PLACERVILLE, Calif. – October 27, 2022 – (Newswire.com)

Terol McCullar (T-Mac) has completed his new book “Hoggs II: Prison Journals”: a gripping and potent work that offers a snapshot of the challenges of the job mixed with insight, humor, and the good and bad decisions of staff.

Terol McCullar actively pursued his 26-year career as a California correctional officer and sergeant instructor known as T-Mac. Having lived through the 1950s and 1960s, combined with his passion for the law and teaching, helped mold his intrinsic belief in self-efficacy. His latent passion as an author has flourished into three published works: both “Hoggs” I and II and a novel, “SICQ.” He looks forward to writing sequels of his offerings and developing into whatever comes next. The author acknowledges the undying support of his wife Tricia, daughters Angela and Marnie, and a growing list of great friends.

Author Terol McCullar (T-Mac) writes, “She either didn’t hear Jason’s shouts or her fear consumed her thoughts. She continued running up the street. Jason turned and went back inside. He hurried to the bedroom and put on some pants and slipped into a pair of shoes. He rushed back outside, but there was no sign of the woman. He sprinted down the steps and headed toward the corner. He turned the corner, but she was nowhere in sight. There were several apartment complexes along the street, and Jason stopped and listened for any commotion. He heard a dog barking and followed the source to a complex on the left side of the street. He walked toward a short cyclone fence, and a dog inside the fence barked at him. He turned and went back into the middle of the street and scanned the streets while he listened for any other noises. Trying to think like an escapee, he surmised that he would head toward a commercial area.”

Published by Newman Springs Publishing, Terol McCullar (T-Mac)’s compelling new book “Hoggs II: Prison Journals” educates readers in the processes used by staff to navigate the changing rules and regulations of the department.

Readers who wish to experience this thought-provoking work can purchase “Hoggs II: Prison Journals” at bookstores everywhere, or online at the Apple iBooks Store, Amazon, or Barnes & Noble.

For additional information or media inquiries, contact Newman Springs Publishing at 732-243-8512.

About Newman Springs Publishing: 

Newman Springs Publishing is a full-service publishing house for serious authors. Each title produced by Newman Springs Publishing undergoes every step of the professional publishing process, including editing, layout, cover design, circulation, distribution, and publicity. All titles are made available in both e-book and print formats. Newman Springs Publishing distributes to tens of thousands of retail outlets throughout North America and internationally. All manuscripts in any genre are welcome to be submitted for review; if the manuscript meets the necessary criteria and is accepted for publication, Newman Springs Publishing will work closely with the author to bring the book to the retail market for a relatively inexpensive initial investment.

Contact Information:

Media Relations

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Author Terol McCullar (T-Mac)’s New Book ‘Hoggs II: Prison Journals’ Offers Unique Insight Into the Eventful and Challenging Lives of Prison Staff